Astana Biomed Group, an authorized Abcam distributor in Central Asia

Human EIF4H knockout HEK-293T cell lysate (ab263184)

Overview

  • Product name

    Human EIF4H knockout HEK-293T cell lysate

  • Product overview


    Knockout cell lysate achieved by CRISPR/Cas9.

  • Parental Cell Line

    HEK293T

  • Organism

    Human

  • Mutation description

    Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.

  • Passage number

  • Knockout validation

    Sanger Sequencing

  • Reconstitution notes

    To use as WB control, resuspend the lyophilizate in 50 µL of LDS* Sample Buffer to have a final concentration of 2 mg/ml. For reducing conditions, we recommend a final concentration of 0.1 M DTT.

    *Usage of SDS sample buffer is not recommended with these lyophilized lysates.

  • Notes

    Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version - found here. Please refer to our lysis protocol for further details on how our lysates are prepared.

    User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

    Access thousands of knockout cell lysates, generated from commonly used cancer cell lines.
    See here for more information on knockout cell lysates.

    Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
    It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

    This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Properties

Target

  • Function

    Stimulates the RNA helicase activity of EIF4A in the translation initiation complex. Binds weakly mRNA.

  • Tissue specificity

    The short isoform is the predominant isoform and is expressed alone in liver and skeletal muscle. Both isoforms are expressed in fibroblast, spleen, testis and bone marrow. Levels are high in lung and pancreas and low in heart, frontal cortex and kidney.

  • Involvement in disease

    Note=EIF4H is located in the Williams-Beuren syndrome (WBS) critical region. WBS results from a hemizygous deletion of several genes on chromosome 7q11.23, thought to arise as a consequence of unequal crossing over between highly homologous low-copy repeat sequences flanking the deleted region. Haploinsufficiency of EIF4H may be the cause of certain cardiovascular and musculo-skeletal abnormalities observed in the disease.

  • Sequence similarities

    Contains 1 RRM (RNA recognition motif) domain.

  • Cellular localization

    Cytoplasm > perinuclear region.
  • Information by UniProt

  • Alternative names

    • AU018978
    • D5Ertd355e
    • E430026L18Rik
    • Ef4h
    • eIF 4H
    • eIF-4H
    • EIF4H
    • Eukaryotic translation initiation factor 4H
    • IF4H_HUMAN
    • KIAA0038
    • WBSCR1
    • Williams Beuren syndrome chromosomal region 1 protein homolog
    • Williams Beuren syndrome chromosome region 1
    • Williams-Beuren syndrome chromosomal region 1 protein
    • Williams-Beuren syndrome chromosome region 1
    • WSCR1
    see all

Properties

Images

  • Sanger Sequencing - Human EIF4H knockout HEK293T cell lysate (ab263184)
    Sanger Sequencing - Human EIF4H knockout HEK293T cell lysate (ab263184)
    Homozygous: 1 bp insertion in exon1

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Clear all

Recently viewed products

Sign up